	US 11,911,460 B1
	Lipid delivery system and virus-like structure (VLS) vaccine constructed therefrom
Qihan Li, Kunming (CN); Kaili Ma, Kunming (CN); Yanmei Li, Kunming (CN); Jingjing Zhang, Kunming (CN); Lichun Wang, Kunming (CN); Changyong Mu, Kunming (CN); Xiaowu Peng, Kunming (CN); Yanrui Su, Kunming (CN); Chang'e Liu, Kunming (CN); Liping He, Kunming (CN); Lin Feng, Kunming (CN); Dongxiu Gao, Kunming (CN); An Wang, Kunming (CN); Hongbing Li, Kunming (CN); Gang Xu, Kunming (CN); Fuyun He, Kunming (CN); Lichun Zheng, Kunming (CN); and Hongkun Yi, Kunming (CN)
Assigned to Weirui Biotechnology (Kunming) Co., LTD., Kunming (CN); and Shandong Weigao Litong Biological Products Co., Ltd., Weihai (CN)
Filed by Weirui Biotechnology (Kunming) Co., LTD., Kunming (CN); and Shandong Weigao Litong Biological Products Co., Ltd., Weihai (CN)
Filed on Aug. 1, 2023, as Appl. No. 18/228,700.
Claims priority of application No. 202310436870.2 (CN), filed on Apr. 23, 2023.
Int. Cl. A61K 39/215 (2006.01); A61P 37/04 (2006.01); A61K 39/00 (2006.01)

CPC A61K 39/215 (2013.01) [A61P 37/04 (2018.01); A61K 2039/53 (2013.01); A61K 2039/55555 (2013.01)]

4 Claims

1. A virus-like structure (VLS) vaccine, comprising a lipid nanoparticle (LNP), wherein the LNP comprises:

a first cationic lipid of ((2-(2-hydroxyethoxy)ethyl)azanediyl)bis(hexane-6,1-diyl)bis(2-hexyldecanoate) (DHA-1),

a second cationic lipid of (2,3-dioleoyl-propyl)-trimethylammonium-chloride (DOTAP),

a phospholipid of 1,2-dioleoyl-SN-glycero-3-phosphocholine (DOPC), and

a polyethylene glycol (PEG)-lipid of methoxypoly(ethylene glycol)-N-tetradecyltetradecanamide-2K (mPEG-DTA-1-2K); and wherein

the LNP encapsulates a non-self-replicating mRNA encoding a SARS-CoV-2 membrane spike (S1) protein; and wherein a surface of the LNP comprises an S1 antigen protein bound to the surface.